Into the future: a single EU body assessing relative effectiveness of medicines?
This article was originally published in SRA
A fully centralized European health technology assessment is probably not a possibility as member states individually are responsible for decisions on access to medicines via their respective national health systems. But what about a central EU expert body responsible for producing a single relative effectiveness assessment that national committees could use in their own HTA and pricing/reimbursement discussions and decisions?
Register for our free email digests: